The objective of this study was two-fold. Firstly, to systematically collect up-to-date published cost data for management (pharmacotherapy) and associated complications (cardiovascular, renal, eye disease and diabetic foot) of type 2 diabetes mellitus in the United Kingdom (UK) for use in the CORE Diabetes Model (CDM). Secondly, where data was scarce, calculations were carried out to estimate the cost inputs for CDM. A systematic literature review (SLR) for published direct medical costs from the UK’s National Health Service and societal perspective was performed in peer-reviewed journals and on government websites in years 2011-2017 in English. The SLR was conducted according to the general principles for undertaking systematic reviews in health care. These methods adhere to the UK’s National Institute for Health and Care Excellence standards for evidence generation. Where the papers did not present primary data the references were explored. A quality assessment of included studies was performed using either the checklist for assessing costing studies or the checklist for assessing cost-effectiveness studies. When conducting calculations, pack sizes, dosages, treatment duration and number of hospital visits were taken into account. All parameters were converted to British Pound and updated to 2016 prices by an inflation factor. The SLR identified 2,472 records of which 52 met the final eligibility criteria. Non-fatal stroke cost was the highest among cardiovascular complications (£7 154), followed by myocardial infarction (£6,706) and congestive heart failure (£3,355). Overall, renal complications were the most costly with renal transplant being the highest (£42,060). Eye disease costs spanned between £109 and £2,557 for retinopathy laser treatment and cataract operation respectively. Diabetic foot amputation cost was £13,926 followed by gangrene treatment at £3,583. Costs are annual. This study presents an updated set of costs for diabetes complications and management for use in the UK setting.